Top Page
Immutep Ltd
(Sydney:IMM)
Immutep Ltd (IMM) vs. iShares MSCI Australia ETF (EWA)
Immutep Ltd Business Overview & Revenue Model
Immutep Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 5.04M | 5.04M | 3.84M | 3.51M | 170.37K | 3.86M |
| Gross Profit | -56.37M | -56.37M | -37.70M | 1.44M | -1.89M | 1.79M |
| EBITDA | -62.88M | -62.88M | -44.54M | -42.88M | -31.87M | -20.72M |
| Net Income | -61.43M | -61.43M | -42.72M | -39.90M | -32.21M | -29.90M |
Balance Sheet | ||||||
| Total Assets | 156.98M | 156.98M | 201.58M | 147.45M | 102.17M | 82.03M |
| Cash, Cash Equivalents and Short-Term Investments | 129.69M | 129.69M | 181.88M | 123.42M | 80.00M | 60.13M |
| Total Debt | 1.63M | 1.63M | 1.59M | 1.23M | 1.73M | 2.82M |
| Total Liabilities | 13.35M | 13.35M | 12.06M | 10.98M | 8.09M | 8.76M |
| Stockholders Equity | 143.64M | 143.64M | 189.52M | 136.47M | 94.08M | 73.27M |
Cash Flow | ||||||
| Free Cash Flow | -62.10M | -62.10M | -35.75M | -35.93M | -30.25M | -17.66M |
| Operating Cash Flow | -62.05M | -62.05M | -34.82M | -35.88M | -30.23M | -17.64M |
| Investing Cash Flow | -38.53M | -38.53M | -21.02M | -31.00K | -22.91K | -15.60K |
| Financing Cash Flow | -525.12K | -525.12K | 95.18M | 76.04M | 50.33M | 52.68M |
Immutep Ltd Technical Analysis
Immutep Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | AU$582.12M | -9.36 | -35.86% | ― | ― | -19.21% | |
48 Neutral | AU$303.20M | -21.22 | -83.97% | ― | 1271.12% | 36.87% | |
47 Neutral | AU$90.02M | -0.89 | -83.09% | ― | ― | 55.94% | |
44 Neutral | AU$404.73M | -81.09 | -27.89% | ― | ― | 67.26% | |
44 Neutral | AU$103.30M | -12.65 | -47.98% | ― | 700.00% | 26.88% | |
41 Neutral | AU$76.13M | -5.26 | -42.68% | ― | ― | 63.46% |
Immutep Ltd Corporate Events
Immutep reported a pivotal quarter marked by a strategic licensing and collaboration deal with Dr. Reddy’s for the commercialisation of eftilagimod alfa in most ex-U.S./EU markets, delivering an upfront payment of about A$30 million and access to up to roughly A$528 million in potential milestones plus royalties, while Immutep retains key-market rights and global manufacturing. The company highlighted strong clinical and regulatory momentum for efti, including robust enrolment and an upcoming futility analysis in the Phase III TACTI-004 lung cancer trial, positive Phase I/II data in first-line non-small cell lung cancer and soft tissue sarcoma, confirmation from the U.S. FDA of a 30 mg optimal biological dose, and encouraging immunosuppressive signals from IMP761 in Phase I; together with a pro-forma cash balance of about A$129.3 million and a French R&D tax incentive, these developments significantly extend Immutep’s cash runway and strengthen its positioning in the competitive oncology and autoimmune immunotherapy landscape.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep reported encouraging interim data from a first-in-human Phase I trial of IMP761, its first-in-class LAG-3 agonist antibody candidate for autoimmune diseases, showing that single-ascending doses at 2.5 and 7 mg/kg were well tolerated with only mild treatment-related effects. The study also demonstrated a clear dose-dependent and long-lasting immunosuppressive effect, with substantial reductions in T cell activity against a strong foreign antigen, reinforcing proof-of-concept that IMP761 may selectively silence dysregulated T cells at inflamed disease sites and potentially offer a more targeted treatment option for major autoimmune indications such as rheumatoid arthritis, Type 1 diabetes and multiple sclerosis; the trial will continue as planned, with further data expected in the first half of 2026, underscoring Immutep’s strategic positioning in the emerging LAG-3 autoimmune therapy market.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced significant progress in its global TACTI-004 (KEYNOTE-F91) Phase III trial, which is evaluating the combination of eftilagimod alfa (efti) and MSD’s KEYTRUDA® for advanced non-small cell lung cancer. The trial has enrolled 289 patients, with over 120 clinical sites activated across 27 countries, including the United States. This progress is bolstered by a recent licensing deal with Dr Reddy’s for emerging markets, and the company remains on track for key milestones, including a futility analysis in early 2026 and full patient enrolment by the third quarter of 2026.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.37 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has entered into a strategic collaboration with Dr. Reddy’s Laboratories for the commercialization of its innovative oncology drug, Eftilagimod Alfa, outside North America, Europe, Japan, and Greater China. This agreement grants Dr. Reddy’s exclusive rights to develop and commercialize the drug in these regions, while Immutep retains manufacturing rights globally and rights in key markets. The collaboration includes an upfront payment of USD 20 million to Immutep, with potential milestone payments and royalties. This partnership is expected to enhance Immutep’s market presence and leverage Dr. Reddy’s capabilities to maximize the drug’s impact, potentially setting a new standard in cancer treatment.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd announced a change in the director’s interest, specifically involving Dr. Russell John Howard. The changes include the acquisition and conversion of performance rights into ordinary shares, as approved by shareholders at recent annual general meetings. This adjustment reflects Dr. Howard’s decision to take a portion of his fees in performance rights, aligning his interests with the company’s long-term growth and shareholder value.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd announced a change in the director’s interest, with Mr. Pete Meyers acquiring 2,058,631 Performance Rights as remuneration for his services. This acquisition, approved at the Annual General Meeting, reflects the company’s strategy to align director compensation with shareholder interests, potentially impacting its governance and stakeholder relations.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced a change in the interest of its director, Lis Boyce, who acquired 707,232 Performance Rights and 166,667 Fully Paid Ordinary Shares. These changes were part of a remuneration package approved at the Annual General Meeting, reflecting the company’s strategy to align director compensation with performance and shareholder interests.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has announced the issuance of 1,800,968 ordinary fully paid securities, which are set to be quoted on the Australian Securities Exchange (ASX) as of December 5, 2025. This move is part of the company’s strategy to enhance its financial position and support its ongoing research and development efforts in the biotechnology sector, potentially impacting its market presence and offering new opportunities for stakeholders.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced the issuance of 4,339,509 performance rights as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This move is likely to enhance employee engagement and align their interests with the company’s growth objectives, potentially strengthening Immutep’s position in the competitive biotechnology market.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced new data from its AIPAC-003 Phase II trial, which will be presented at the 2025 San Antonio Breast Cancer Symposium. The trial evaluated the combination of eftilagimod alfa (efti) and paclitaxel in heavily pretreated metastatic breast cancer patients, achieving strong objective response rates and immune activation. The study successfully met the FDA’s Project Optimus requirements, establishing 30 mg as the optimal biological dose for efti, which is crucial for ongoing and future clinical programs. This development is strategically important for Immutep’s oncology pipeline, including its global Phase III trial with MSD’s KEYTRUDA® for non-small cell lung cancer.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.28 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Ltd’s recent presentation at their Annual General Meeting 2025 provided an update on the company’s business activities. The presentation emphasized the company’s ongoing efforts and strategic plans, although it included forward-looking statements subject to various risks and uncertainties. Stakeholders are advised to consider these factors carefully, as actual results may differ from current expectations.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited announced promising results from its EFTISARC-NEO Phase II trial, which were presented at the CTOS 2025 Annual Meeting. The trial demonstrated significant tumor hyalinization/fibrosis in patients with soft tissue sarcoma (STS) using a novel combination of eftilagimod alfa (efti) with radiotherapy and KEYTRUDA. This combination showed a strong immune response, potentially leading to better patient outcomes and survival rates. The findings suggest that efti could be beneficial in treating early-stage cancers, expanding its role in the cancer treatment landscape.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
Immutep Limited has received a €2,588,954 (~ A$4,567,769) R&D tax incentive payment from the French Government under the Crédit d’Impôt Recherche scheme. This funding will support the global clinical development of eftilagimod alfa and IMP761, enhancing Immutep’s operations and potentially strengthening its position in the biotechnology industry.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.50 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.